Semax vs Selank: Nootropic Peptide Research Comparison
Semax and Selank are both synthetic heptapeptides that emerged from the same Russian peptide-pharmacology research tradition, built on a shared design logic — a short bioactive fragment extended with a stabilizing Pro-Gly-Pro tripeptide — yet they are investigated in almost entirely different research contexts. In a semax vs selank comparison, Semax is studied primarily as a neurotrophic and cognitive-signaling research peptide linked to BDNF-associated pathways and monoaminergic systems, while Selank is studied primarily in anxiolytic-pattern behavioral research models and immunomodulatory signaling tied to its tuftsin-derived lineage. This guide places both compounds side by side across mechanism, structural chemistry, analytical verification, and laboratory handling, strictly as research-use-only compounds intended for in-vitro and preclinical research models — not for human or animal therapeutic application.
What Are Semax and Selank? Classification and Research Origins
Before any mechanism-level comparison is useful, it helps to place Semax and Selank correctly within the broader taxonomy of peptide research compounds. Both are classified as synthetic regulatory peptides — short, engineered chains built from a core bioactive fragment of a larger endogenous peptide or protein, rather than isolated wholesale from a biological source. Both fall under the umbrella that research literature and research-supply catalogs generally describe as “nootropic peptides” or “cognitive/neuro-signaling peptides,” though as this guide details below, that shared umbrella term understates how differently the two compounds are actually studied.
Semax and Selank are commonly attributed to the same lineage of Russian peptide-pharmacology research programs that, over several decades, pursued a specific engineering strategy: identify a short, biologically active fragment within a larger endogenous peptide or protein, then extend that fragment with a stabilizing tripeptide sequence to improve its behavior in research systems. This shared design philosophy is precisely why the two compounds are so frequently discussed together in comparative literature and research-sourcing contexts, even though the fragments each is built from originate from entirely unrelated physiological systems — a distinction explored fully in the structural chemistry section below.
For sourcing purposes, Semax is cataloged within the cognitive and nootropic peptides research category, alongside other compounds studied for central-nervous-system-adjacent research questions — see the Semax 10mg research peptide listing for current lot-specific specifications and documentation. Selank is not currently offered as a standalone product on Royal Peptide Labs, but it is referenced throughout this guide as an essential comparison point for any laboratory evaluating Semax against the broader field of structurally related nootropic-adjacent research peptides.
The table below summarizes the core classification parameters a research team typically wants before designing a comparative protocol.
| Parameter | Semax | Selank |
|---|---|---|
| Compound class | Synthetic heptapeptide, ACTH-fragment-derived | Synthetic heptapeptide, tuftsin-derived |
| Primary research category | Neurotrophic / cognitive-signaling peptide | Anxiolytic-pattern / immunomodulatory-signaling peptide |
| Parent bioactive fragment | ACTH(4-7) corticotropin fragment | Tuftsin (immunomodulatory tetrapeptide) |
| Stabilizing motif | C-terminal Pro-Gly-Pro extension | C-terminal Pro-Gly-Pro extension |
| Supplied research form | Lyophilized powder, research-use-only | Lyophilized powder, research-use-only (where sourced) |
| Common literature grouping | Nootropic / neuro-signaling peptide research | Anxiolytic-pattern peptide research; sometimes grouped adjacently under nootropic-peptide literature due to CNS-model overlap |
That last row is worth sitting with for a moment, because it is the source of most confusion in this comparison: Selank is grouped near Semax in casual research-supply taxonomy largely because both are short, Russian-lineage, Pro-Gly-Pro-stabilized peptides studied in central-nervous-system-adjacent research models — not because their underlying receptor pharmacology overlaps. The sections that follow unpack exactly where that overlap ends.
Structural Chemistry: Two Heptapeptides Built From Different Parent Molecules
Semax and Selank are both seven-amino-acid peptide chains — heptapeptides — and both follow the same two-part construction logic: a short core sequence borrowed from a larger endogenous peptide, followed by a C-terminal Pro-Gly-Pro tripeptide addition. That shared architecture is where the structural similarity ends.
Semax: An ACTH-Fragment-Derived Construct
Semax’s documented amino acid sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues (Met-Glu-His-Phe) correspond to a fragment of adrenocorticotropic hormone, specifically the ACTH(4-7) region, a segment of the larger ACTH molecule that in its native context is associated with the hypothalamic-pituitary-adrenal signaling axis rather than with direct corticosteroid-release activity. Researchers characterizing Semax describe it as retaining the ACTH(4-7) fragment’s central-nervous-system-relevant signaling properties while being engineered away from the hormonal, adrenal-stimulating activity associated with the full-length ACTH molecule — a design rationale specific to this compound’s development history.
Selank: A Tuftsin-Derived Construct
Selank’s documented amino acid sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues (Thr-Lys-Pro-Arg) correspond exactly to tuftsin, a naturally occurring tetrapeptide fragment derived from the Fc region of immunoglobulin G. Tuftsin is well characterized in classical immunology literature as an immunomodulatory signaling peptide associated with phagocytic-cell activity. Selank’s design extends this immunomodulatory tetrapeptide core with the same Pro-Gly-Pro stabilizing tripeptide used in Semax, applying an identical engineering strategy to an entirely different starting fragment.
The Shared Pro-Gly-Pro Motif: Convergent Design, Divergent Cores
The rationale documented for the Pro-Gly-Pro C-terminal extension shared by both peptides is enzymatic stability — this tripeptide sequence is reported to reduce susceptibility to peptidase-mediated degradation relative to the unextended parent fragment alone, a property relevant to how long each compound’s structure persists intact within a research system before enzymatic breakdown. This is a chemistry-driven design choice common to both molecules, not a claim about any specific research outcome. It is also the single structural feature that most directly explains why Semax and Selank are so often catalogued and discussed side by side: from a pure sequence-engineering standpoint, they were built using the same template, even though the biologically active fragment inserted into that template differs completely between the two.
Molecular Size and Physical Form
Both peptides fall into the small-peptide size class — seven residues each — which places them at the smaller end of the research-peptide spectrum relative to larger, multi-domain compounds studied elsewhere in incretin or growth-hormone-axis peptide research. Both are supplied as lyophilized, white to off-white powders for research use, which is the standard physical form for small, hydrophilic peptides of this kind, since lyophilization avoids the stability challenges of storing short peptides in aqueous solution over extended periods.
Structural Comparison Table
| Structural Feature | Semax | Selank |
|---|---|---|
| Documented sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Parent fragment (residues 1-4) | ACTH(4-7) corticotropin fragment | Tuftsin (IgG Fc-derived tetrapeptide) |
| C-terminal stabilizing tripeptide | Pro-Gly-Pro | Pro-Gly-Pro |
| Chain length | 7 residues | 7 residues |
| Supplied physical form | Lyophilized powder | Lyophilized powder |
| Parent physiological system | Hypothalamic-pituitary-adrenal-adjacent signaling | Immune / phagocytic-cell signaling |
Researchers new to this compound pair often assume that shared chain length and a shared stabilizing motif imply overlapping pharmacology. As the mechanism section below details, that assumption does not hold — the parent fragment, not the stabilizing tripeptide, is what determines which receptor systems and research models each compound is actually relevant to.
Mechanism of Action: Divergent Pathways Under a Shared Design Philosophy
Once the structural picture is clear, the mechanism-level divergence between Semax and Selank becomes the central organizing fact of this comparison. Despite their shared heptapeptide chassis, the two compounds are investigated in research models built around entirely different signaling systems.
Semax: Neurotrophic and Monoaminergic Research Angles
Semax is most commonly investigated in research models examining its association with brain-derived neurotrophic factor (BDNF) expression and related neurotrophin signaling pathways. BDNF is a well-characterized signaling protein involved in neuronal survival, synaptic plasticity research, and neurodevelopmental research more broadly, and Semax’s research literature frequently centers on whether and how introduction of the peptide into a research model influences BDNF-associated gene expression or downstream neurotrophin signaling. Alongside neurotrophin-focused work, Semax has also been examined in research contexts touching on monoaminergic systems — dopaminergic and serotonergic signaling pathways relevant to cognitive-performance and neuroprotection research models — and in research related to enzymatic regulation of catecholamine turnover, an angle that appears repeatedly in the compound’s mechanism-focused literature.
Selank: GABAergic, Serotonergic, and Immunomodulatory Research Angles
Selank’s mechanism-focused research diverges sharply from Semax’s. Owing to its tuftsin-derived parent fragment, Selank is investigated in research models examining immunomodulatory signaling — consistent with tuftsin’s established role in classical immunology research as a phagocytic-activity-associated peptide. Separately, and somewhat independently of its immune-adjacent lineage, Selank has become a subject of central-nervous-system research interest specifically in anxiolytic-pattern behavioral research models, where investigators examine its association with GABAergic signaling and serotonergic turnover in model systems designed to probe anxiety-pattern behavior without the sedative-pattern confounds associated with some benzodiazepine-class reference compounds. This dual research identity — immunomodulatory on one hand, anxiolytic-pattern-behavioral on the other — is a distinguishing feature of Selank’s literature that has no clean analog in Semax’s research profile.
Why “Nootropic” Is an Imprecise Umbrella for Both
Calling both compounds “nootropic peptides” is a common shorthand in research-supply contexts, but it blurs more than it clarifies. Semax’s neurotrophic and monoaminergic research focus fits reasonably well within a cognitive-signaling framing. Selank’s anxiolytic-pattern and immunomodulatory research focus is a different research category entirely — one that happens to overlap with cognitive-peptide research programs because anxiety-pattern and cognitive-performance behavioral assays are frequently run in adjacent or even the same laboratories, using similar rodent behavioral-testing infrastructure. Researchers designing a study around either compound should resist the shorthand and instead select the compound whose actual mechanism-level research literature matches their specific research question.
Mechanism Comparison Table
| Mechanism-Level Research Focus | Semax | Selank |
|---|---|---|
| Primary signaling system studied | BDNF / neurotrophin-associated signaling | GABAergic / serotonergic signaling |
| Secondary signaling system studied | Monoaminergic (dopaminergic/serotonergic) systems | Immunomodulatory / phagocytic-cell signaling |
| Typical behavioral research model class | Cognitive-performance, neuroprotection-pattern models | Anxiolytic-pattern behavioral models |
| Research lineage driving mechanism focus | ACTH-fragment / HPA-axis-adjacent research history | Tuftsin / immune-signaling research history |
The remainder of this guide builds on this mechanism-level divergence to compare the two compounds’ research applications, analytical verification needs, and laboratory handling — all of which are shaped, directly or indirectly, by these differing pathway-level research questions.
Semax in Research Models: Neurotrophic and Cognitive-Signaling Focus
Semax’s research literature spans several tiers of model system, each suited to a different level of question about its neurotrophic and cognitive-signaling research profile.
In-Vitro and Cell-Culture Research
At the cellular level, Semax is examined in neuronal culture models designed to probe gene expression and signaling changes associated with neurotrophin pathways, including BDNF-related expression assays. These systems allow researchers to isolate molecular-level signaling questions from the added complexity of a whole-animal research model, and are typically the first tier used to characterize a new batch or lot of the compound before it is introduced into a more complex system.
Rodent Cognitive-Performance Research Models
A substantial share of Semax’s research literature involves rodent behavioral research models designed around cognitive-performance and learning-related tasks. These model systems are used to investigate whether introduction of the peptide into the research model is associated with measurable changes in task-performance behavior, typically alongside biochemical assays examining neurotrophin expression in relevant brain regions harvested from the same research model. This guide does not describe or summarize outcome data from any specific study — researchers should consult primary, peer-reviewed sources for outcome-level information, several of which are linked in the references section below.
Neuroprotection-Pattern Research Models
Separately from cognitive-performance research, Semax has been examined in research models associated with neuroprotection-pattern research questions, including rodent models used broadly across the neuroscience research field to investigate cellular stress and recovery-pattern signaling in neural tissue. Semax’s research role in these models is typically framed around its neurotrophin-signaling profile — the same BDNF-associated mechanism discussed in the previous section — rather than a distinct, unrelated mechanism specific to neuroprotection research alone.
Monoamine-System Research Models
A smaller but consistent thread of Semax’s research literature examines its association with monoaminergic signaling systems, including research contexts related to catecholamine turnover and enzymatic regulation within that system. This research angle is often pursued using biochemical assay systems measuring monoamine or monoamine-metabolite levels in tissue samples from a research model, in parallel with the behavioral and neurotrophin-focused research described above.
Model Selection Considerations for Semax-Focused Research
- Cell-culture systems are appropriate for isolating molecular-level neurotrophin signaling questions with high experimental control.
- Rodent cognitive-performance models are appropriate for behavioral-level research questions but require careful task selection matched to the specific cognitive domain under investigation.
- Neuroprotection-pattern models require researchers to clearly define the specific stress or injury paradigm being used, since “neuroprotection research” spans a wide range of distinct experimental paradigms in the broader literature.
- Monoamine-system assays typically require tissue-level biochemical analysis rather than purely behavioral readouts, and should be planned alongside — not as a substitute for — behavioral research components.
Laboratories building a Semax-focused research program are well served by reviewing the dedicated Semax research guide, which covers the compound’s classification, mechanism, and handling requirements in greater depth than is practical within a comparative article.
Selank in Research Models: Anxiolytic-Pattern and Immunomodulatory Signaling
Selank’s research literature is organized around two research threads that, while both traceable to its tuftsin-derived structure, address quite different scientific questions.
Anxiolytic-Pattern Behavioral Research Models
The larger of Selank’s two research threads involves rodent behavioral research models designed to probe anxiety-pattern behavior — commonly using standardized behavioral-testing paradigms widely used across the anxiolytic-research field generally, such as elevated-maze-type and open-field-type behavioral assays. A recurring research question in this literature is whether Selank’s association with anxiolytic-pattern behavioral changes in these models occurs without the sedative-pattern or motor-coordination confounds associated with some benzodiazepine-class reference compounds — a distinguishing research question that has motivated a meaningful share of Selank’s behavioral-pharmacology literature specifically.
GABAergic and Serotonergic Signaling Research
Underlying the behavioral research described above, a parallel thread of Selank’s literature investigates its association with GABAergic signaling and serotonergic turnover at the biochemical level, using tissue-level assays in parallel with, or independent of, behavioral testing. This research angle situates Selank within the broader anxiolytic-pharmacology research field, alongside small-molecule and peptide research compounds studied for similar GABA- and serotonin-system-adjacent research questions.
Immunomodulatory Research Models
Because Selank’s core four-residue fragment is tuftsin itself, a distinct — and mechanistically separate — thread of Selank’s research literature examines immunomodulatory signaling in research models involving phagocytic-cell activity and related immune-signaling readouts. This research direction is a direct extension of tuftsin’s own well-established immunology research history, predating Selank’s own development, and represents a research application with essentially no analog in Semax’s literature.
Why Selank’s Research Identity Is Genuinely Dual
Unlike Semax, whose neurotrophic and monoaminergic research threads are broadly complementary facets of a single cognitive-signaling research identity, Selank’s anxiolytic-pattern-behavioral research and its immunomodulatory research represent two largely independent scientific questions that happen to be investigated using the same molecule. Researchers designing a Selank-focused study should be explicit about which of these two research threads their specific protocol addresses, since a behavioral-pharmacology-focused laboratory and an immunology-focused laboratory are likely to be interested in entirely different assay endpoints, reference compounds, and model systems, despite studying the identical peptide.
Model Selection Considerations for Selank-Focused Research
| Research Thread | Typical Model System | Typical Assay Endpoint |
|---|---|---|
| Anxiolytic-pattern behavior | Rodent behavioral-testing paradigms | Behavioral-pattern scoring, activity tracking |
| GABAergic / serotonergic signaling | Tissue-level biochemical assay systems | Neurotransmitter or metabolite quantification |
| Immunomodulatory signaling | Immune-cell / phagocytic-activity research models | Immune-cell activity or signaling-marker assays |
This dual research identity is one of the clearest points of departure between Selank and Semax, and it is central to why a well-designed semax vs selank comparison cannot simply treat the two as interchangeable members of a single “nootropic peptide” category.
Semax vs Selank: Head-to-Head Research Comparison at a Glance
With mechanism, structure, and research-model context established, it is useful to consolidate the semax vs selank comparison into a single reference table before moving into the more specialized sections on analytical verification, storage, and sourcing that follow.
| Comparison Point | Semax | Selank |
|---|---|---|
| Parent bioactive fragment | ACTH(4-7) corticotropin fragment | Tuftsin (immunomodulatory tetrapeptide) |
| Documented sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Primary research category | Neurotrophic / cognitive-signaling | Anxiolytic-pattern behavioral / immunomodulatory |
| Key signaling systems studied | BDNF-associated neurotrophin signaling; monoaminergic systems | GABAergic and serotonergic signaling; immune/phagocytic-cell signaling |
| Typical behavioral model class | Cognitive-performance, neuroprotection-pattern models | Anxiolytic-pattern behavioral models |
| Research identity structure | Single, complementary cognitive-signaling focus | Dual, largely independent behavioral and immunomodulatory foci |
| Chain length / class | Heptapeptide | Heptapeptide |
| Stabilizing motif | C-terminal Pro-Gly-Pro | C-terminal Pro-Gly-Pro |
| Supplied research form | Lyophilized powder | Lyophilized powder (where sourced) |
| Analytical verification method | HPLC (purity) + MS (identity) | HPLC (purity) + MS (identity) |
| RPL product category | Cognitive & nootropic peptides | Comparison reference only; not currently a standalone RPL product |
Two conclusions fall directly out of this table. First, the structural and handling parallels between Semax and Selank are genuine — both are short, stabilized, lyophilized research peptides requiring the same analytical rigor and the same general storage discipline. Second, the mechanism and research-application rows show almost no overlap, which means the choice between them in an actual research protocol should be driven entirely by the specific pathway or behavioral endpoint under investigation, not by their shared design lineage.
A related comparison worth reviewing alongside this one is the Semax vs. Noopept research comparison, which places Semax against a structurally unrelated small-molecule-derived nootropic research compound rather than another Russian-lineage heptapeptide, offering a useful contrast in comparison methodology.
Shared Research Lineage: Why These Two Peptides Are Constantly Compared
Given how little mechanistic overlap exists between Semax and Selank, it is worth directly addressing why the two are so persistently discussed as a pair in research-supply catalogs, comparative articles, and laboratory-sourcing conversations.
A Common Engineering Template
As detailed in the structural chemistry section above, both compounds were built using the same fragment-plus-stabilizing-tripeptide design template, applied by researchers working within the same general peptide-engineering research tradition. This shared engineering approach — rather than any shared receptor pharmacology — is the historical root of their persistent pairing in the literature and in research-sourcing contexts.
Shared Handling and Analytical Profile
Because both are small, lyophilized, Pro-Gly-Pro-stabilized heptapeptides, they present nearly identical practical considerations for a research laboratory: similar analytical verification requirements (HPLC purity assessment and mass-spectrometry identity confirmation), similar storage and reconstitution handling, and similar research-use-only sourcing considerations. A laboratory that has already built internal protocols around handling Semax will find that most of that protocol infrastructure transfers directly to handling Selank, even though the actual experiments run with each compound will look nothing alike.
Overlapping Laboratory Infrastructure
Both compounds are frequently studied using rodent behavioral-testing infrastructure — even though the specific behavioral paradigms differ (cognitive-performance tasks for Semax-focused work, anxiety-pattern paradigms for Selank-focused work), the underlying animal-housing, handling, and behavioral-testing equipment overlaps substantially. Laboratories with an established central-nervous-system behavioral-research program are consequently well positioned to take on either compound without major new infrastructure investment, which reinforces their pairing in practical, sourcing-driven contexts even where the science itself diverges.
A Useful Comparison, Properly Framed
None of this means the semax vs selank comparison is scientifically empty — quite the opposite. Understanding precisely where two structurally similar, commonly co-sourced research peptides diverge mechanistically is itself a valuable exercise for any laboratory building a nootropic- or CNS-adjacent research program, because it clarifies that structural family membership is not a reliable proxy for pharmacological similarity. That lesson generalizes well beyond this specific pair, and is one of the more durable takeaways a comparative-pharmacology framing can offer a research team evaluating any set of structurally related peptides.
Receptor and Pathway Divergence: Where the Research Splits
Moving beyond the general mechanism overview above, it is worth examining more specifically how the downstream research literatures for Semax and Selank diverge at the level of signaling pathway and research community.
Semax’s Downstream Research Threads
Research examining Semax’s association with neurotrophin signaling frequently extends into downstream intracellular signaling cascades associated with neurotrophin receptor activity, including research questions touching on kinase-signaling pathways implicated broadly in neuronal survival and synaptic-plasticity research. This body of literature tends to cluster with — and cite — research on neurotrophin biology, ischemia-pattern neuroprotection research, and cognitive-neuroscience research more broadly, forming a fairly coherent citation community centered on neurotrophic signaling.
Selank’s Downstream Research Threads
Selank’s literature, by contrast, splits into two citation communities that rarely reference one another. Its anxiolytic-pattern behavioral research tends to cluster with, and cite, the broader anxiolytic-pharmacology and behavioral-neuroscience research literature — a citation community focused on GABA-receptor pharmacology, serotonergic-system research, and behavioral-testing methodology. Its immunomodulatory research, meanwhile, clusters with — and cites — classical tuftsin and phagocytic-signaling immunology literature, a citation community with essentially no overlap with behavioral neuroscience.
Why This Divergence Matters for Research Design
A researcher designing a comparative study that regards Semax and Selank as parallel members of a single research category risks conflating findings from citation communities that do not actually speak to one another. A behavioral-pharmacology finding involving Selank’s anxiolytic-pattern research says little about its immunomodulatory research profile, and neither says anything directly comparable to Semax’s neurotrophin-focused literature. Recognizing these separate citation communities — rather than treating “nootropic peptide research” as a single undifferentiated literature — is essential to designing a scientifically coherent comparative protocol.
A Practical Framework for Navigating the Divergence
- When searching the literature for Semax, expect the most directly relevant results to cluster around neurotrophin signaling, monoaminergic systems, and cognitive-performance or neuroprotection-pattern behavioral research.
- When searching the literature for Selank’s behavioral research, expect relevant results to cluster around GABAergic/serotonergic pharmacology and anxiolytic-pattern behavioral-testing methodology — a distinct search strategy from Semax-focused searches.
- When searching the literature for Selank’s immunomodulatory research, expect relevant results to reference tuftsin and phagocytic-cell signaling research directly, often independent of any CNS-behavioral framing at all.
- Treat each of these three threads as requiring its own dedicated literature search — a single combined search strategy risks missing large portions of the relevant, applicable literature for whichever specific research question is actually under investigation.
This is precisely why the references section at the end of this guide provides separate, targeted search links for each compound and research thread, rather than a single combined search query that would understate the genuine diversity of the underlying literature.
Structure-Activity Considerations and Fragment-Based Peptide Design
Stepping back from Semax and Selank specifically, both compounds are useful case studies in a broader peptide-engineering strategy worth understanding on its own terms: fragment-based design, in which a short, biologically active segment of a larger endogenous peptide or protein is isolated and then modified to improve its research utility.
Why Fragment-Based Design Is Attractive for CNS-Adjacent Research
Large endogenous peptides and proteins are often impractical as direct research tools — their size can complicate synthesis, their multi-domain structure can make it difficult to isolate which region is responsible for a specific signaling property, and their size can raise questions about central-nervous-system-relevant distribution research. Identifying the minimal fragment responsible for a specific signaling property of interest, and then studying that fragment (potentially with added stabilizing modifications) in isolation, is a well-established structure-activity relationship (SAR) research strategy applied broadly across peptide pharmacology — not a strategy unique to Semax or Selank.
The Role of the Stabilizing Tripeptide
Both compounds append the same Pro-Gly-Pro tripeptide to their respective core fragment. This is a documented example of a broader SAR research principle: short peptide fragments are often highly susceptible to rapid enzymatic degradation once introduced into a biological research system, and appending a modestly sized, proline-rich stabilizing sequence is one recognized strategy for improving a short fragment’s persistence in such a system, without fundamentally altering the fragment’s own sequence or, in principle, its receptor-level activity.
Fragment Selection as the Primary Determinant of Research Relevance
The comparison between Semax and Selank illustrates a broader SAR research lesson clearly: the choice of which fragment to isolate and extend is the single most consequential design decision in fragment-based peptide engineering — far more consequential than the choice of stabilizing modification appended afterward. Two heptapeptides built with an identical stabilizing strategy but different parent fragments end up studied in almost entirely different research fields, precisely because the fragment itself — not the broader engineering template — carries the biological signaling information relevant to receptor engagement.
Implications for Evaluating Other Fragment-Derived Research Peptides
Laboratories encountering other fragment-derived research peptides beyond Semax and Selank should apply the same evaluative lens: identify the parent fragment and its documented physiological signaling context first, and treat any shared engineering template (stabilizing modifications, conjugation strategies, or chain-length class) as a secondary, largely non-predictive consideration when assessing likely research relevance to a specific pathway or behavioral question.
| SAR Design Element | Predictive of Research Relevance? | Why |
|---|---|---|
| Parent bioactive fragment | Yes — primary determinant | Carries the sequence information responsible for receptor/pathway engagement |
| Stabilizing tripeptide (e.g., Pro-Gly-Pro) | No — secondary consideration | Improves persistence in a research system without altering core signaling identity |
| Overall chain length class | No — secondary consideration | Relevant to handling/synthesis, not to receptor-level pharmacology |
Analytical Purity and How It’s Verified (HPLC/MS)
Regardless of how differently Semax and Selank behave mechanistically, the analytical verification standard a research laboratory should demand of either compound is identical — and non-negotiable for any protocol where reproducibility matters.
High-Performance Liquid Chromatography (HPLC)
Reverse-phase HPLC (RP-HPLC) is the standard method for assessing purity in short synthetic peptides like Semax and Selank — the proportion of a sample corresponding to the intended, correctly synthesized full-length heptapeptide versus truncated or deletion sequences that can arise during solid-phase peptide synthesis. Even at a chain length of only seven residues, incomplete coupling steps during synthesis can generate detectable impurity peaks, which is why a purity percentage derived from HPLC peak-area analysis remains essential documentation regardless of a peptide’s small size.
Mass Spectrometry (MS)
Mass spectrometry complements HPLC by confirming molecular identity — verifying that the dominant chromatographic peak corresponds to the expected molecular weight of Semax or Selank specifically, rather than to a co-eluting synthesis byproduct or an entirely different compound. Given how structurally similar Semax and Selank are at a superficial level (both short, Pro-Gly-Pro-stabilized heptapeptides), independent mass confirmation is particularly relevant for this compound pair — a labeling or fulfillment error between two similarly sized, similarly packaged research peptides would not necessarily be caught by a purity check alone, but would be readily identified by a mass spectrometry identity check.
Reading a Certificate of Analysis for Either Compound
A complete, lot-specific certificate of analysis (COA) for Semax or Selank should include a lot or batch identifier, an HPLC purity result, a mass spectrometry identity confirmation, appearance and solubility notes consistent with a correctly synthesized lyophilized peptide, and the testing date and testing source. Royal Peptide Labs publishes lot-specific documentation on its certificate of analysis (COA) page, and researchers evaluating Semax specifically should cross-reference the COA associated with the lot listed on the Semax 10mg product page before beginning experimental work.
Why Small Peptide Size Does Not Mean Simple Verification
A common misconception is that shorter peptides like Semax and Selank require less analytical scrutiny than larger, more structurally complex research compounds. In practice, the verification standard should not change with size — a seven-residue peptide with a truncated or substituted residue is just as capable of producing confounded research data as an impurity in a much larger molecule, and because short peptides are relatively inexpensive and fast to synthesize, the temptation to skip rigorous per-lot testing is, if anything, greater in this size class, which makes independent verification more important, not less.
| Documentation Element | What It Confirms | Why It Matters for Semax and Selank Specifically |
|---|---|---|
| HPLC purity trace | Proportion of full-length peptide vs. impurities | Even short chains can carry synthesis-related deletion impurities |
| Mass spectrometry result | Correct molecular identity | Distinguishes two similarly sized, similarly packaged heptapeptides from one another |
| Lot-specific COA | Traceability to the specific vial in hand | Avoids reliance on generic, non-lot-specific documentation |
For a deeper technical treatment of how these two verification methods complement each other, see the HPLC vs. mass spectrometry peptide testing comparison, and for a broader treatment of what a research-grade purity claim should actually document, see research peptide purity: what to look for.
Storage, Reconstitution, and Handling for Laboratory Research
Because Semax and Selank share the same general physical class — small, lyophilized, Pro-Gly-Pro-stabilized heptapeptides — their storage and reconstitution handling requirements are, in practice, nearly identical, even where their downstream research applications are not.
Pre-Reconstitution Storage
Lyophilized Semax and Selank should both be stored frozen, protected from light, and sealed against moisture exposure prior to reconstitution, consistent with standard handling practice for small lyophilized research peptides generally. Vials should be allowed to reach room temperature before opening to reduce condensation risk inside the vial, a precaution that applies equally to both compounds.
Reconstitution Technique
Reconstitution — dissolving the lyophilized peptide in an appropriate diluent to prepare a stock solution for research use — follows the same general technique for both compounds:
- Diluent selection — bacteriostatic water is a commonly used diluent in peptide research settings for solutions expected to be used across multiple laboratory sessions, given its preservative content; sterile water without preservative may be preferred for single-use assay preparations. See the dedicated guidance on bacteriostatic water for research use for a fuller treatment.
- Gentle mixing — diluent should be added slowly along the vial wall rather than directly onto the lyophilized cake, with gentle swirling rather than shaking, to minimize aggregation risk at the air-liquid interface.
- Visual inspection — a properly reconstituted solution of either peptide should appear clear; cloudiness or particulate matter suggests a reconstitution or stability issue warranting investigation before use in any assay.
- Concentration planning — target stock concentrations should be calculated based on the specific assay’s requirements before reconstitution, since repeated dilution and re-concentration is not advisable for small peptide solutions.
A full walkthrough of reconstitution technique and math, applicable across the research-peptide category broadly, is available in the peptide storage and reconstitution guide.
Post-Reconstitution Storage and Stability
Once reconstituted, both Semax and Selank solutions should generally be stored refrigerated and used within the timeframe indicated by supplier stability data or the research team’s own stability characterization. Neither compound carries the additional lipid-conjugate handling considerations relevant to larger, fatty-acid-modified research peptides elsewhere in the research-peptide category — their handling profile is comparatively straightforward, which is one practical advantage of working with this size class of compound.
Storage Comparison Table
| Handling Stage | Semax | Selank |
|---|---|---|
| Pre-reconstitution storage | Frozen, light-protected, sealed | Frozen, light-protected, sealed |
| Reconstitution diluent | Bacteriostatic or sterile water, per protocol | Bacteriostatic or sterile water, per protocol |
| Post-reconstitution storage | Refrigerated, within supplier-indicated window | Refrigerated, within supplier-indicated window |
| Notable handling caveats | Standard small-peptide handling; no lipid-conjugate considerations | Standard small-peptide handling; no lipid-conjugate considerations |
This near-identical handling profile is a genuine practical convenience for laboratories running comparative protocols involving both compounds, even though — as emphasized throughout this guide — the experimental design and research questions attached to each remain distinct.
Selecting Between Semax and Selank for a Research Protocol
Given everything established above, the practical question a research team ultimately needs to answer is straightforward to frame, even if the underlying science is nuanced: which compound matches the specific pathway or behavioral endpoint the protocol is designed to investigate?
When a Neurotrophic / Cognitive-Signaling Research Design Points to Semax
Research protocols centered on BDNF-associated neurotrophin signaling, monoaminergic-system research questions, cognitive-performance behavioral assays, or neuroprotection-pattern research models align most directly with Semax’s established research literature. Laboratories building a cognitive-signaling research program should generally treat Semax as the more literature-supported starting point for this class of question.
When an Anxiolytic-Pattern or Immunomodulatory Research Design Points to Selank
Research protocols centered on anxiolytic-pattern behavioral research, GABAergic or serotonergic signaling questions, or immunomodulatory and phagocytic-cell-signaling research questions align most directly with Selank’s literature. Laboratories should also be explicit internally about which of Selank’s two research threads — behavioral or immunomodulatory — a given protocol addresses, since, as discussed above, these represent largely independent research questions investigated using the same compound.
When a Comparative or Paired-Probe Design Uses Both
Some research designs deliberately pair Semax and Selank within the same behavioral-pharmacology screen, using their divergent mechanism-level research profiles to help dissociate cognitive-performance endpoints from anxiety-pattern endpoints within a single model system — treating each compound as a contrasting reference probe rather than as interchangeable options. This design approach is discussed further in the comparative study designs section below.
A Decision Framework
| Research Question | More Literature-Supported Compound |
|---|---|
| BDNF / neurotrophin signaling research | Semax |
| Cognitive-performance behavioral research | Semax |
| Neuroprotection-pattern research models | Semax |
| Monoaminergic-system research | Semax |
| Anxiolytic-pattern behavioral research | Selank |
| GABAergic / serotonergic signaling research | Selank |
| Immunomodulatory / phagocytic-signaling research | Selank |
| Dissociating cognitive vs. anxiety-pattern endpoints in one model | Both, as paired contrasting probes |
This decision framework is intentionally literature-driven rather than based on general reputation or shared structural family — a distinction this guide has returned to repeatedly, because it is the single most important methodological takeaway a semax vs selank comparison can offer a research team.
Sourcing Considerations: What to Look for in a Supplier
Whichever compound a research protocol calls for, the quality of any resulting research finding depends directly on the quality and documentation of the material sourced. This section outlines what a research buyer should evaluate before selecting a supplier for Semax, Selank, or any structurally comparable research peptide.
Documentation Transparency
A supplier serious about supporting legitimate research should make lot-specific COAs readily accessible and tied to the specific batch a laboratory actually receives, rather than a generic or previously issued document. Vague, undated, or non-lot-specific purity claims are a signal to look elsewhere, regardless of how reputable a supplier’s general marketing appears.
Testing Methodology and Independence
Beyond simply publishing a COA, it matters who performed the testing and by what method. In-house HPLC/MS testing is a reasonable baseline; third-party verification adds an additional layer of confidence by removing any incentive conflict between the entity synthesizing a peptide and the entity certifying its purity. Researchers building a long-term sourcing relationship should ask directly whether COAs reflect in-house testing, third-party testing, or both, and Royal Peptide Labs details its own approach on its quality testing page and certifications page.
Packaging, Labeling, and Cold-Chain Handling
Because both Semax and Selank are lyophilized peptides sensitive to temperature and moisture exposure, appropriate packaging — light-protected, properly sealed vials — and shipping practices that avoid unnecessary thermal excursions in transit are genuine quality indicators, not cosmetic packaging concerns. Labeling should clearly indicate lot number, research-use-only status, and storage requirements upon receipt.
Research-Use-Only Framing and Compliance Posture
A supplier’s marketing and labeling language is itself a quality signal. Suppliers that frame products strictly around research applications, avoid therapeutic or outcome-based claims, and clearly state research-use-only status are more likely to be operating within a compliance framework appropriate for this category — which matters practically as well as ethically, since it reduces the risk of relying on a supplier whose broader claims are not grounded in verifiable science.
Supplier Evaluation Checklist
| Evaluation Criterion | What to Look For |
|---|---|
| Lot-specific COA availability | Published or easily requestable, tied to the exact lot received |
| Testing methodology disclosed | HPLC + MS at minimum; ideally third-party verified |
| Labeling accuracy | Research-use-only stated clearly; no therapeutic claims |
| Storage/shipping practices | Appropriate packaging; minimal thermal excursion risk |
| Product-specific documentation | Specifications matched to the exact SKU, e.g. the Semax 10mg listing, not a generic catalog entry |
None of these evaluation criteria are unique to Semax or Selank, but they carry particular weight for a compound pair this frequently confused with one another in casual sourcing contexts — a labeling or fulfillment error between two similarly packaged heptapeptides is precisely the kind of mistake rigorous COA cross-referencing is designed to catch.
Common Research Questions and Misconceptions
Beyond the mechanistic and sourcing questions already covered, research teams evaluating Semax and Selank together frequently encounter a recurring set of misconceptions worth addressing directly.
Misconception: Structural Similarity Implies Pharmacological Similarity
As this guide has emphasized throughout, Semax and Selank share a chain-length class and a stabilizing motif, but their parent fragments come from entirely unrelated physiological systems. Structural family membership at the level of “short, Pro-Gly-Pro-stabilized heptapeptide” is not a reliable predictor of shared receptor or pathway engagement, and research teams should not assume interchangeability based on this shared design template alone.
Misconception: Selank Is Simply a “Calmer” Version of Semax
Because both compounds are frequently marketed together under a broad nootropic-peptide umbrella, a common informal characterization frames Selank as a more sedating or “calming” counterpart to a more “stimulating” Semax. This framing is imprecise: Selank’s anxiolytic-pattern research literature specifically emphasizes investigation of anxiolytic-pattern behavior without the sedative-pattern confounds associated with classic sedating reference compounds, and Semax’s research literature is not organized around a “stimulating” mechanism claim at all — it centers on neurotrophin and monoaminergic-signaling research questions. Reducing either compound to a simple stimulating-versus-calming binary misrepresents both bodies of literature.
Misconception: One Compound Is Simply “Better Researched” Than the Other
Both compounds have a substantial, decades-spanning research literature attached to them, but the literatures address different questions rather than one being a strictly larger or more rigorous version of the other. A fair comparison requires evaluating literature depth within each compound’s own relevant research thread, not comparing raw publication counts across fundamentally different research categories.
Misconception: RUO Framing Is a Formality Rather Than a Real Constraint
Both compounds are supplied strictly for in-vitro laboratory and research use, and this designation reflects the genuine state of their characterization rather than a marketing or legal formality layered on top of otherwise different content. Neither compound’s research literature should be read as establishing appropriateness for any application outside a controlled research setting, and this guide’s consistently research-first framing is a deliberate reflection of that constraint.
A Quick-Reference Myth-Versus-Reality Table
| Common Claim | More Accurate Framing |
|---|---|
| “Same family, so interchangeable” | Same engineering template; different parent fragment and research application |
| “Selank is the calming one, Semax is the stimulating one” | Each has its own distinct, non-binary mechanism-level research literature |
| “One is better researched than the other” | Each has substantial literature within its own distinct research thread |
| “RUO labeling is just a formality” | RUO framing reflects the genuine current state of research characterization |
Comparative Study Designs: Studying Semax and Selank Together
Although Semax and Selank address largely separate research questions individually, a meaningful category of research design deliberately studies them together — not because they are interchangeable, but because their divergent mechanism-level profiles make them useful as contrasting reference probes within the same experimental system.
Paired-Probe Designs for Dissociating Behavioral Endpoints
Behavioral-pharmacology research models frequently need to dissociate cognitive-performance changes from anxiety-pattern behavioral changes, since the two can confound one another in a poorly controlled design — an anxious research-model subject, for instance, may perform differently on a cognitive-performance task for reasons unrelated to the cognitive pathway under investigation. Pairing a neurotrophic/cognitive-signaling-focused compound like Semax with an anxiolytic-pattern-focused compound like Selank within the same overall study — run as separate treatment arms rather than combined — allows researchers to characterize each compound’s association with its respective behavioral domain within a shared experimental framework, improving cross-arm comparability.
Design Considerations for Comparative Protocols
- Separate treatment arms — Semax and Selank should generally be studied as distinct treatment groups within a shared model system, rather than co-administered, so that any observed association can be attributed to a specific compound.
- Matched reference/control groups — a properly controlled comparative design requires vehicle-only and, where relevant, positive-control reference arms appropriate to each compound’s specific research thread (a cognitive-performance reference for the Semax arm, an anxiolytic-pattern reference for the Selank arm).
- Blinding — behavioral-pattern scoring in particular benefits from blinded assessment, given the subjective elements involved in many standardized behavioral-testing paradigms.
- Consistent lot sourcing — as emphasized throughout this guide, lot-specific COA documentation should be maintained and cross-referenced for both compounds throughout a comparative study’s duration, to avoid confounding treatment-arm differences with unaccounted-for lot-to-lot variability.
Why This Design Approach Is Distinct From a Head-to-Head Efficacy Comparison
It is worth being explicit that a comparative study design pairing Semax and Selank is not typically framed as asking “which compound performs better” — because the two are not investigated as competing solutions to the same research question. Rather, this design approach uses each compound’s distinct, well-characterized research profile as a tool for isolating a specific behavioral domain within a broader experimental system, a methodologically different goal from a direct efficacy comparison between two compounds targeting the same pathway.
Reporting Considerations
Any resulting research communication from a comparative Semax/Selank study design should clearly frame each compound’s role within the study — specifying which treatment arm addressed which research question — rather than implying a single unified “semax vs selank” outcome comparison, which would misrepresent the actual experimental logic of a paired-probe design.
The Broader 2026 Nootropic Peptide Research Landscape
Semax and Selank sit within a wider research landscape that has continued to expand alongside interest in metabolic and growth-hormone-axis peptide research, though CNS-adjacent peptide research follows its own distinct trajectory worth situating explicitly.
Growing Interest in Peptide-Based CNS Research Tools
As of 2026, research interest in peptide-based probes for central-nervous-system-adjacent signaling questions continues to grow alongside — and in some respects in contrast to — small-molecule nootropic research compounds. Peptide-based tools like Semax and Selank offer researchers a degree of target-region and pathway specificity that some small-molecule alternatives do not, which is part of why this research category has sustained scientific interest even as pharmaceutical development attention has, in the broader industry, concentrated heavily on metabolic-pathway peptide research in recent years.
Expanding Comparative and Mechanism-Resolution Literature
The literature specifically addressing how Semax’s and Selank’s divergent mechanisms map onto downstream signaling cascades has continued to expand, consistent with a broader trend across peptide pharmacology research toward higher-resolution mechanism characterization rather than purely behavioral or phenomenological research designs. This mirrors a pattern seen elsewhere in peptide research more broadly, where early literature tends to establish broad associations and later literature works to resolve the specific signaling pathways underlying those associations.
Methodological Advances Relevant to This Research Category
Advances in behavioral-testing standardization, tissue-level signaling-assay sensitivity, and small-peptide analytical verification technology have made it increasingly feasible to characterize short research peptides like Semax and Selank with a level of mechanistic and analytical rigor that would have been more difficult to achieve with earlier-generation research tools. This methodological progress benefits the entire nootropic- and CNS-adjacent peptide research category, not just this specific compound pair.
Where This Research Category Appears to Be Heading
Within the nootropic-peptide research category specifically, ongoing research directions include finer characterization of the neurotrophin-signaling pathways associated with Semax, continued resolution of the GABAergic/serotonergic mechanisms associated with Selank’s anxiolytic-pattern research, and growing interest in defining more precisely where Selank’s behavioral and immunomodulatory research threads intersect, if at all, at the level of shared upstream signaling. Laboratories tracking this space should expect continued growth in the searchable literature base — the references section below links directly to searchable PubMed and ClinicalTrials.gov queries that will surface new entries as they are indexed, rather than relying on a static summary.
For a broader view of the research category these compounds belong to, see the nootropic peptides: cognitive research compounds explained overview, which situates Semax and Selank alongside other CNS-adjacent research peptides under active investigation.
Safety and Handling Notes for Laboratory Personnel
Because Semax and Selank are supplied strictly for in-vitro laboratory and research use, handling practices should follow standard laboratory biosafety and chemical-handling protocols applicable to peptide research generally — the same rigor applied to any bioactive research compound.
Personal Protective Equipment
Standard laboratory PPE — gloves, eye protection, and a lab coat — should be worn when handling lyophilized peptide material and when preparing reconstituted solutions of either compound, consistent with an institution’s standard operating procedures for bioactive research compound handling. Because lyophilized peptide powder can become airborne during handling, particularly when opening vials, work should be conducted in a manner that minimizes aerosolization, such as within a fume hood or biosafety cabinet where institutional protocols call for it.
Spill and Waste Handling
Spilled lyophilized material or reconstituted solution of either Semax or Selank should be handled according to institutional chemical waste protocols. Because research peptides of this kind are bioactive at the pathway level in the research systems under study, they should not be treated as biologically inert for disposal purposes — institutional environmental health and safety guidance should govern disposal of both waste solution and any contaminated consumables.
Labeling and Chain-of-Custody Practices
Reconstituted stock solutions and working dilutions of either compound should be clearly labeled with compound identity, concentration, reconstitution date, and preparer initials at minimum. This is standard laboratory practice, but it takes on particular importance for this specific compound pair — as emphasized throughout this guide, Semax and Selank are visually and physically similar as lyophilized powders and reconstituted solutions alike, and a labeling error between the two in a shared laboratory freezer or refrigerator is a genuinely plausible failure mode that clear, consistent labeling is specifically designed to prevent.
Research-Use-Only Scope Boundaries
All handling, storage, and experimental use of Semax and Selank sourced through Royal Peptide Labs should remain within the bounds of in-vitro laboratory and research applications. This guide does not provide, and should not be interpreted as providing, guidance for any application outside that scope. Laboratory personnel and institutional oversight bodies, such as an Institutional Biosafety Committee where applicable, should be consulted regarding any institution-specific requirements beyond the general practices summarized here.
Documentation for Reproducibility
- Record reconstitution date and diluent lot alongside each compound’s own lot number.
- Track the number of freeze-thaw cycles for any aliquoted, reconstituted solution of either compound.
- Note storage temperature excursions if a freezer or refrigerator event is logged during either compound’s storage window.
- Retain the COA associated with each lot alongside experimental records for that lot, rather than filed separately where it may become disconnected from the data it supports.
- Maintain clearly distinct, unambiguous labeling for Semax versus Selank vials and solutions at every handling stage, given their physical similarity as lyophilized research peptides.
Frequently Asked Questions
What is the main research difference between Semax and Selank?
Semax is studied primarily as a neurotrophic and cognitive-signaling research peptide, with research literature centered on BDNF-associated neurotrophin signaling and monoaminergic systems. Selank is studied primarily in anxiolytic-pattern behavioral research models and in immunomodulatory signaling research tied to its tuftsin-derived structure. Despite a shared engineering template, the two address largely separate research questions.
Are Semax and Selank structurally related?
Both are synthetic heptapeptides built using the same design template — a short bioactive fragment extended with a stabilizing Pro-Gly-Pro tripeptide — but the core fragment each is built from differs completely. Semax is derived from an ACTH(4-7) corticotropin fragment, while Selank is derived from tuftsin, an immunomodulatory tetrapeptide fragment of immunoglobulin G.
Which signaling systems are studied with each peptide?
Semax’s research literature centers on BDNF-associated neurotrophin signaling and monoaminergic (dopaminergic/serotonergic) systems. Selank’s research literature centers on GABAergic and serotonergic signaling in anxiolytic-pattern behavioral research, as well as immunomodulatory signaling connected to its tuftsin lineage.
Can Semax and Selank be studied together in the same research model?
Yes, some comparative research designs pair the two compounds as separate treatment arms within the same behavioral-pharmacology study, using their divergent mechanism-level profiles to help dissociate cognitive-performance endpoints from anxiety-pattern endpoints within one experimental system.
How is purity verified for Semax and Selank research samples?
Both are verified using reverse-phase HPLC for purity assessment and mass spectrometry for molecular identity confirmation, documented on a lot-specific certificate of analysis. This dual-method approach is especially relevant for this compound pair given how visually and physically similar the two lyophilized peptides are.
What research models are commonly used to study these peptides?
Semax is studied in neuronal cell-culture systems, rodent cognitive-performance behavioral models, and neuroprotection-pattern research models. Selank is studied in rodent anxiolytic-pattern behavioral models, tissue-level GABAergic/serotonergic signaling assays, and immune-cell or phagocytic-activity research models.
How should Semax and Selank be stored prior to reconstitution?
Both should be stored frozen, protected from light, and sealed against moisture exposure prior to reconstitution, following standard handling practice for small lyophilized research peptides. Vials should reach room temperature before opening to reduce condensation risk.
Is Selank studied for immune-related research questions?
Yes. Because Selank’s core fragment is tuftsin itself — an established immunomodulatory tetrapeptide — a distinct thread of Selank’s research literature examines immunomodulatory signaling in research models involving phagocytic-cell activity, separate from its anxiolytic-pattern behavioral research thread.
Does Semax’s research focus exclusively on BDNF-associated signaling?
No. While BDNF-associated neurotrophin signaling is a major research thread for Semax, its literature also includes research on monoaminergic systems, including catecholamine-turnover-related research, alongside cognitive-performance and neuroprotection-pattern behavioral research models.
What should a laboratory look for when sourcing either peptide?
A lot-specific certificate of analysis documenting both HPLC purity and mass spectrometry identity confirmation, transparent testing methodology, research-use-only labeling, and appropriate cold-chain packaging practices. Given how similar Semax and Selank are as lyophilized powders, cross-referencing the COA against the specific product listing and lot received is especially important for this compound pair.
Scientific References
The following are live search links into PubMed and ClinicalTrials.gov, rather than citations to specific papers, so that researchers always land on the current, indexed literature rather than a static and potentially outdated reference list.
- Semax neuroprotective peptide research — PubMed search
- Semax BDNF expression research — PubMed search
- Selank anxiolytic peptide research — PubMed search
- Selank tuftsin analog immunomodulatory research — PubMed search
- ACTH(4-10) fragment cognitive research — PubMed search
- Nootropic peptide heptapeptide research — PubMed search
- Semax — ClinicalTrials.gov search
- Selank — ClinicalTrials.gov search
All products and information from Royal Peptide Labs are intended strictly for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.